Next generation bioconjugates for intra- and extracellular targeting

C.P.R. Hackenberger, Berlin/D

Prof. Dr. Christian P. R. Hackenberger, Humboldt Universität zu Berlin and Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP) Robert-Rössle-Str. 10, 13125 Berlin, Germany
Email: hackenbe@fmp-berlin.de,
www.fmp-berlin.info/hackenbe, Twitter: @PhosphorusFive

In this presentation, I will focus on the chemical modification of functional proteins for for pharmaceutical and medicinal applications.[1] In my laboratory, we use a combined approach of recently developed chemoselective reactions and enzymatic ligations, for instance the so-called P5- or Tub-tag®-labeling,[2,3] for bioconjugation. By generating stable antibody-drug conjugates (ADCs),[3] structurally defined multivalent scaffolds[4] or cell-permeable antibodies via conjugating cyclic cell-penetrating peptides,[5] we provide new modalities for most challenging pharmaceutical targets, including next generation cancer therapeutics or novel inhibitors against viral infections.

References

[1] D. Schumacher, C.P.R. Hackenberger, *Curr. Opin. Chem. Biol.* **2014**, *22*, 62-69.
[2] a) M.-A. Kasper et al., *Angew. Chem. Int. Ed*. **2019**, *58*, 11625-11630; b) M.-A. Kasper et al., *Angew. Chem. Int. Ed*. **2019**, *58*, 11631-11636; c) M.-A. Kasper et al., *Chem Sci.* **2019**, *10*, 6322-6329; d) C.E. Stieger et al. *Angew. Chem. Int. Ed*. **2021**, *60*, 15359-15364.
[3] a) D. Schumacher et al., *Angew. Chem. Int. Ed.* **2015**, *54(46)*, 13787-13791, b) D. Schumacher et al., *Chem. Sci.* **2017**, *8*, 3471-3478.
[4] D. Lauster et al., *Nature Nanotech.* **2020**, 15, 373-379.
[5] a) N. Nischan et al., *Angew. Chem. Int. Ed.* **2015**, *54(6)*, 1950-1953; b) H. Herce et al., *Nature Chem.* **2017**, *9*, 762-771; c) A.F.L. Schneider et al., *Nature Chem.* **2021**, *13*, 530-539.